Compare VALU & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALU | AKBA |
|---|---|---|
| Founded | 1931 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.1M | 380.4M |
| IPO Year | 1995 | 2014 |
| Metric | VALU | AKBA |
|---|---|---|
| Price | $35.92 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 959.0 | ★ 2.6M |
| Earning Date | 03-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | 8.91 | ★ 93.94 |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $36,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.74 | ★ N/A |
| Revenue Growth | ★ 1.08 | N/A |
| 52 Week Low | $35.15 | $1.14 |
| 52 Week High | $41.85 | $4.08 |
| Indicator | VALU | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 51.53 |
| Support Level | $35.15 | $1.30 |
| Resistance Level | $38.09 | $1.55 |
| Average True Range (ATR) | 0.47 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 37.22 | 34.62 |
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.